ArticleJournal of pain research2025
Evolution of the Quality of Life of Long-Term Fibromyalgia Users of Millimeter Wave-Based Neuromodulation: A Real-World Retrospective Study.
Article in Journal of pain research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Fibromyalgia (FM) is a widespread pain condition, associated with other symptoms such as fatigue, sleep disorders, stiffness, and mood disturbances. It significantly impacts patients' quality of life (QoL) and poses a substantial challenge due to the lack of a definitive cure. This study aimed to report real-world data on the long-term use (18 months) of a millimeter (MMW)-based neuromodulation device and tracking application, and its effects on various health dimensions in a self-declared FM population. Methods: This retrospective study was based on data including daily MMW wristband use and health parameters assessed at baseline (D0) and tracked weekly (pain, stiffness and fatigue) or quarterly (QoL, quality of sleep and impression of change). The primary inclusion criteria were a self-reported diagnosis of FM and consistent device usage for a minimum of 18 months. Results: The inclusion criteria were met by 185 users. There was a reduction in the Fibromyalgia Impact Questionnaire (FIQ) scores, with an average reduction of 27% after the first three months (M3), indicating improved QoL, and stabilization thereafter. Similar improvements were observed in sleep quality, stiffness and fatigue. In contrast, pain intensity showed a continuous decline throughout the 18-month period. Conclusion: The significant improvements in QoL, pain intensity, and sleep quality, maintained over time, underline the MMW device's ability to provide sustained relief and enhance daily lives of people with FM.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.